A S Dharmadhikari1, M Mphahlele2, K Venter2, A Stoltz3, R Mathebula2, T Masotla2, M van der Walt2, M Pagano4, P Jensen5, E Nardell1. 1. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. South African Medical Research Council, Pretoria, South Africa. 3. University of Pretoria, Pretoria, South Africa. 4. Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA. 5. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Effective treatment for drug-susceptible tuberculosis (TB) rapidly renders patients non-infectious, long before conversion of sputum acid-fast smear or culture to negative. Multidrug-resistant TB (MDR-TB) patients on treatment are currently assumed to remain infectious for months. While the resources required for prolonged hospitalization are a barrier to the scale-up of MDR-TB treatment, the safety of community treatment is clear. OBJECTIVES: To estimate the impact of treatment on infectiousness among MDR-TB patients. METHODS: A series of five human-to-guinea pig TB transmission studies was conducted to test various interventions for infection control. Guinea pigs in adjacent chambers were exposed to exhaust air from a hospital ward occupied by mostly sputum smear- and culture-positive MDR-TB patients. The guinea pigs then underwent tuberculin skin testing for infection. Only the control groups of guinea pigs from each study (no interventions used) provide the data for this analysis. The number of guinea pigs infected in each study is reported and correlated with Mycobacterium tuberculosis drug susceptibility relative to treatment. RESULTS: Despite exposure to presumably infectious MDR-TB patients, infection percentages among guinea pigs ranged from 1% to 77% in the five experiments conducted. In one experiment in which guinea pigs were exposed to 27 MDR-TB patients newly started on effective treatment for 3 months, there was minimal transmission. In four other experiments with greater transmission, guinea pigs had been exposed to patients with unsuspected extensively drug-resistant tuberculosis who were not on effective treatment. CONCLUSIONS: In this model, effective treatment appears to render MDR-TB patients rapidly non-infectious. Further prospective studies on this subject are needed.
BACKGROUND: Effective treatment for drug-susceptible tuberculosis (TB) rapidly renders patients non-infectious, long before conversion of sputum acid-fast smear or culture to negative. Multidrug-resistant TB (MDR-TB) patients on treatment are currently assumed to remain infectious for months. While the resources required for prolonged hospitalization are a barrier to the scale-up of MDR-TB treatment, the safety of community treatment is clear. OBJECTIVES: To estimate the impact of treatment on infectiousness among MDR-TBpatients. METHODS: A series of five human-to-guinea pigTB transmission studies was conducted to test various interventions for infection control. Guinea pigs in adjacent chambers were exposed to exhaust air from a hospital ward occupied by mostly sputum smear- and culture-positive MDR-TBpatients. The guinea pigs then underwent tuberculin skin testing for infection. Only the control groups of guinea pigs from each study (no interventions used) provide the data for this analysis. The number of guinea pigs infected in each study is reported and correlated with Mycobacterium tuberculosis drug susceptibility relative to treatment. RESULTS: Despite exposure to presumably infectious MDR-TBpatients, infection percentages among guinea pigs ranged from 1% to 77% in the five experiments conducted. In one experiment in which guinea pigs were exposed to 27 MDR-TBpatients newly started on effective treatment for 3 months, there was minimal transmission. In four other experiments with greater transmission, guinea pigs had been exposed to patients with unsuspected extensively drug-resistant tuberculosis who were not on effective treatment. CONCLUSIONS: In this model, effective treatment appears to render MDR-TBpatients rapidly non-infectious. Further prospective studies on this subject are needed.
Authors: Joia S Mukherjee; Michael L Rich; Adrienne R Socci; J Keith Joseph; Felix Alcántara Virú; Sonya S Shin; Jennifer J Furin; Mercedes C Becerra; Donna J Barry; Jim Yong Kim; Jaime Bayona; Paul Farmer; Mary C Smith Fawzi; Kwonjune J Seung Journal: Lancet Date: 2004-02-07 Impact factor: 79.321
Authors: Ashwin S Dharmadhikari; Randall J Basaraba; Martie L Van Der Walt; Karin Weyer; Matsie Mphahlele; Kobus Venter; Paul A Jensen; Melvin W First; Sydney Parsons; David N McMurray; Ian M Orme; Edward A Nardell Journal: Tuberculosis (Edinb) Date: 2011-04-07 Impact factor: 3.131
Authors: A Roderick Escombe; David A J Moore; Robert H Gilman; William Pan; Marcos Navincopa; Eduardo Ticona; Carlos Martínez; Luz Caviedes; Patricia Sheen; Armando Gonzalez; Catherine J Noakes; Jon S Friedland; Carlton A Evans Journal: PLoS Med Date: 2008-09-16 Impact factor: 11.069
Authors: Judith R Glynn; Jennifer Whiteley; Pablo J Bifani; Kristin Kremer; Dick van Soolingen Journal: Emerg Infect Dis Date: 2002-08 Impact factor: 6.883
Authors: Nicole Salazar-Austin; Alvaro A Ordonez; Alice Jenh Hsu; Jane E Benson; Mahadevappa Mahesh; Elizabeth Menachery; Jafar H Razeq; Max Salfinger; Jeffrey R Starke; Aaron M Milstone; Nicole Parrish; Eric L Nuermberger; Sanjay K Jain Journal: Lancet Infect Dis Date: 2015-11-16 Impact factor: 25.071
Authors: R R Nathavitharana; P Daru; A E Barrera; S M Mostofa Kamal; S Islam; M Ul-Alam; R Sultana; M Rahman; Md S Hossain; P Lederer; S Hurwitz; K Chakraborty; N Kak; D B Tierney; E Nardell Journal: Int J Tuberc Lung Dis Date: 2017-09-01 Impact factor: 2.373
Authors: Palwasha Y Khan; Tom A Yates; Muhammad Osman; Robin M Warren; Yuri van der Heijden; Nesri Padayatchi; Edward A Nardell; David Moore; Barun Mathema; Neel Gandhi; Vegard Eldholm; Keertan Dheda; Anneke C Hesseling; Valerie Mizrahi; Roxana Rustomjee; Alexander Pym Journal: Lancet Infect Dis Date: 2018-12-13 Impact factor: 25.071
Authors: Leonardo Martinez; Renu Verma; Julio Croda; C Robert Horsburgh; Katharine S Walter; Nicholas Degner; Keren Middelkoop; Anastasia Koch; Sabine Hermans; Digby F Warner; Robin Wood; Frank Cobelens; Jason R Andrews Journal: Eur Respir J Date: 2019-06-27 Impact factor: 16.671
Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: K G Castro; S M Marks; M P Chen; A N Hill; J E Becerra; R Miramontes; C A Winston; T R Navin; R H Pratt; K H Young; P A LoBue Journal: Int J Tuberc Lung Dis Date: 2016-07 Impact factor: 2.373